HALF YEAR RESULTS 2022
Andreas Eckert, CEO
11 August 2022
1
A Diversified Global Specialist for Radioactive Applications
ISOTOPE
PRODUCTS
Industry
Radiation
Sources
Services
Trade
Disposal
MEDICAL
Medicine
Medical Devices
Pharmaceuticals
Lab Devices
Engineering
Others
Group Items/
Pipeline
Holding
Pentixa
Myelo
Special projects
Engine
+++
106.8 million EUR Revenues in Q2 2022
2
15.4 million EUR Net Income
957 Employees (Headcounts)
19 Sites Worldwide
Results Q2-2022
(EUR million)
Since January 3rd, 2022
Tecnonuclear
3 Buenos Aires
Revenues
106.8
Net Income
15.4
NI/ Sales = 14%
2%
9%
43%
46%
America
Europe
Asia
Middle East & Africa
Slides only for illustration - the spoken word shall be binding
Growing Profits,
Growing Dividends
Dividend/ share in EUR
(share splitt adjusted)
Net Income in mm EUR
x 2,5
x 2,4
4
In the Middle of an Expanding Specialty Pharma Market
5
Um den Rest dieser Noodl zu lesen, rufen Sie bitte die Originalversion auf, und zwar hier.
Attachments
Disclaimer
Eckert & Ziegler AG published this content on 11 November 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 11 November 2022 17:11:06 UTC.